Reference health
A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer
52/52 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 52 checked references that resolve
resolves10.1097/JTO.0b013e3181c6f035
First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review
resolves10.1002/ijc.29915
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
resolves10.1146/annurev.med.55.091902.104433
The erbB Family: Targets for Therapeutic Development Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase Inhibitors
resolves10.1016/S0140-6736(09)60569-9
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
resolves10.1093/annonc/mds214
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
resolves10.1016/S1470-2045(12)70412-6
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
resolves10.1200/JCO.2012.44.2806
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With
<i>EGFR</i>
Mutations
resolves10.1007/s12094-013-1143-9
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
resolves10.1016/j.cllc.2014.12.013
Current and Future Approaches in the Management of Non–Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
resolves10.1016/j.molonc.2014.05.003
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
resolves10.1177/1758834011427576
Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls
resolves10.2174/156800909789271495
Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
resolves10.1158/1078-0432.CCR-06-2077
Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib
resolves10.1016/j.lungcan.2015.01.004
Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations
resolves10.1016/j.ctrv.2011.07.008
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors
resolves10.1093/jnci/92.18.1472
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
resolves10.1158/1078-0432.CCR-04-1070
Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871
resolves10.1158/1078-0432.CCR-07-1109
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor
resolves10.1158/1535-7163.MCT-07-0070
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling
<i>in vitro</i>
and inhibits insulin-like growth factor-I receptor–dependent tumor growth
<i>in vivo</i>
resolves10.4155/fmc.09.89
Discovery of OSI-906: A Selective and Orally Efficacious Dual Inhibitor of the IGF-1 Receptor and Insulin Receptor
resolves10.1158/1535-7163.MCT-13-0598
Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
resolves10.1158/1078-0432.CCR-10-2054
The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
resolves10.1158/0008-5472.CAN-06-2000
Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation
resolves10.1097/JTO.0b013e3181a52359
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer
resolves10.1016/j.cllc.2013.12.006
Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Non–Small-Cell Lung Cancer
resolves10.1093/annonc/mdn727
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients
resolves10.4161/mabs.3.3.15188
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
resolves10.1016/j.abb.2012.03.016
Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition
resolves10.1080/19420862.2016.1160989
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
resolves10.1200/JCO.2009.26.2386
Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma
resolves10.2174/187152008783497055
Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
resolves10.1200/JCO.2005.11.437
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
resolves10.1200/JCO.2008.20.2630
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
resolves10.3390/ijms131216020
Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
resolves10.1158/1078-0432.CCR-07-0938
A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer
resolves10.1136/gut.2007.137802
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model
resolves10.1158/1078-0432.CCR-04-2290
A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma
resolves10.1371/journal.pone.0116610
Quantitative Analysis of Ligand-EGFR Interactions: A Platform for Screening Targeting Molecules
resolves10.1021/jm9002395
Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach
resolves10.1007/s13277-015-4028-4
Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances
resolves10.1158/1078-0432.CCR-09-2699
A Bispecific Enediyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Shows Potent Antitumor Activity
resolves10.1016/j.canlet.2010.02.020
A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice
resolves10.1097/CAD.0000000000000029
An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity
resolves10.1097/CAD.0000000000000160
A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity
resolves10.1007/s00262-014-1604-1
Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation
resolves10.1016/S0022-1759(98)00127-6
Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent—application to a human single-chain Fv fragment
resolves10.1158/1078-0432.CCR-06-2454
Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv
The 4 references without a DOI — listed, not checked
no DOI — not checkedTreatment of advanced non small cell lung cancer
no DOI — not checkedDalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer
no DOI — not checkedAntitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40)
no DOI — not checkedA diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.18632/oncotarget.15933"><img src="https://citestamp.com/citestamped/10.18632/oncotarget.15933/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.18632/oncotarget.15933)